source
- EnGene shares tumble 80% after Phase 2 bladder cancer data raise safety concernsEnGene, a Canadian biotech firm, released updated Phase 2 results for its experimental therapy aimed at a specific group of bladder cancer patients. The company said the new data fell short of expe…
- Political appointee stalls Sanofi drug approval, raising concerns about FDA interferenceSTAT's D.C. Diagnosis newsletter reports that a political appointee is impeding the approval of a Sanofi drug, suggesting direct political interference at the FDA. The article notes that the appoi…